There is a fundamental educational responsibility for a procedure that has the potential to disrupt a decades-old standard of care. The Vascular Quality Initiative (VQI) transcarotid artery revascularization (TCAR) Surveillance Project (TSP) has great practical worth in this regard through its rapid acquisition of real-world data. One example is Dr. Marc Schermerhorn’s analysis of local bleeding after TCAR and its reduction with protamine reversal of heparin (after a test dose) compared to no protamine, constituting an extremely important safety signal.

As worldwide experience with TCAR continues to rapidly accrue, it is also our responsibility at Silk Road Medical to ensure that new learnings are shared with physicians who wish to offer this therapy to their patients, so that pitfalls may be avoided and potential complications are managed effectively with the best possible outcomes. In this Endovascular Today supplement, we seek to share those insights to support you in the development of your TCAR programs.

Sumaira Macdonald, MD, PhD, MBChB, MRCP, FRCP, FRCR
Executive Medical Director | Silk Road Medical